FDA panel backs new diabetes drug

Share this article:
An FDA advisory panel on Friday endorsed Bristol-Myers Squibb's and Merck's Pargluva, developed to control blood sugar levels and cholesterol in people with Type-2 diabetes.
Members of the FDA's Endocrinologic and Metabolic Drugs advisory committee voted 8-1 to recommend approval of Pargluva to treat Type 2 diabetes alone. The panel voted 7-2 to endorse its use alongside another treatment, metformin.
However, the panel also voted 6-3 against recommending Pargluva's use in combination with sulfonylurea, another drug that prompts the pancreas to release more natural insulin into the bloodstream.
Although it is not required to do so, the FDA usually follows the advice of its advisory panels.
Share this article:

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.